News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
509,263 Results
Type
Article (35038)
Company Profile (75)
Press Release (474150)
Section
Business (145892)
Career Advice (2356)
Deals (26553)
Drug Delivery (81)
Drug Development (70115)
Employer Resources (135)
FDA (12961)
Job Trends (11559)
News (260127)
Policy (25665)
Tag
Academia (2392)
Alliances (36120)
Alzheimer's disease (1222)
Approvals (12899)
Artificial intelligence (116)
Bankruptcy (294)
Best Places to Work (9430)
Breast cancer (111)
Cancer (975)
Cardiovascular disease (99)
Career advice (1978)
Cell therapy (207)
Clinical research (55880)
Collaboration (319)
Compensation (84)
COVID-19 (2308)
C-suite (102)
Data (1058)
Diabetes (139)
Diagnostics (5301)
Earnings (51917)
Employer resources (124)
Events (69002)
Executive appointments (300)
FDA (13435)
Funding (306)
Gene therapy (167)
GLP-1 (545)
Government (3907)
Healthcare (15272)
Infectious disease (2390)
Inflammatory bowel disease (96)
Interviews (512)
IPO (11865)
Job creations (2419)
Job search strategy (1626)
Layoffs (358)
Legal (5322)
Lung cancer (170)
Manufacturing (143)
Medical device (10031)
Medtech (10035)
Mergers & acquisitions (14744)
Metabolic disorders (374)
Neuroscience (1497)
NextGen Class of 2024 (5205)
Non-profit (3780)
Northern California (1214)
Obesity (205)
Opinion (179)
Parkinson's disease (73)
Patents (97)
People (48287)
Phase I (17130)
Phase II (24632)
Phase III (18818)
Pipeline (438)
Postmarket research (2188)
Preclinical (6903)
Radiopharmaceuticals (196)
Rare diseases (193)
Real estate (3788)
Regulatory (17606)
Research institute (1980)
Resumes & cover letters (342)
Southern California (1080)
Startups (2520)
United States (10515)
Vaccines (475)
Weight loss (157)
Date
Today (107)
Last 7 days (681)
Last 30 days (3162)
Last 365 days (29655)
2024 (27193)
2023 (33022)
2022 (43267)
2021 (46248)
2020 (44754)
2019 (38060)
2018 (28839)
2017 (25872)
2016 (24462)
2015 (28631)
2014 (21276)
2013 (17139)
2012 (18309)
2011 (19388)
2010 (17118)
Location
Africa (678)
Arizona (108)
Asia (31560)
Australia (6703)
California (2662)
Canada (1116)
China (212)
Colorado (116)
Connecticut (110)
Europe (69940)
Florida (393)
Georgia (90)
Illinois (271)
Indiana (162)
Kansas (77)
Maryland (493)
Massachusetts (1855)
Michigan (138)
Minnesota (195)
New Jersey (777)
New York (773)
North Carolina (547)
Northern California (1214)
Ohio (110)
Pennsylvania (633)
South America (935)
Southern California (1080)
Texas (366)
Utah (81)
Washington State (296)
509,263 Results for "bergenbio as".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
BerGenBio First Quarter Results 2024: Advancing to the Next Stage of Development
BerGenBio ASA, a clinical-stage bio-pharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced financial results for the quarter ended March 31, 2024, and provided a business update.
May 29, 2024
·
3 min read
Business
BerGenBio Announces NCI Clinical Collaboration with UT Health San Antonio and Sobi®
BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced that it has entered into a clinical trial agreement with the Mays Cancer Center at The University of Texas Health Science Center at San Antonio and Swedish Orphan Biovitrum AB, a specialized international biopharmaceutical company.
May 28, 2024
·
4 min read
Drug Development
BerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer Patients with a STK11 mutation
BerGenBio ASA (OSE: BGBIO) announced today it has initiated the Phase 2a portion of the BGBC016 clinical study of its selective AXL inhibitor bemcentinib in combination with standard of care therapy in first-line Non Small Cell Lung Cancer (NSCLC) patients harboring a STK11 mutation (STK11m).
March 20, 2024
·
3 min read
Business
BerGenBio Reports Third Quarter 2023 Financial Results
BerGenBio ASA announced financial results for the quarter ended September 30, 2023, and provided a business update.
November 14, 2023
·
10 min read
BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that Dr. Mirella Spalluto of the University of Southampton today presented “Investigating the effects of AXL inhibition during respiratory viral infections” during the 6th Forum on Respiratory Infections in Glasgow, Scotland.
February 7, 2024
·
3 min read
BerGenBio Announces Poster Presentation at Upcoming SITC Meeting
BerGenBio ASA today announced that a poster highlighting data from pre-planned biomarker analyses in second line Non-Small Cell Lung Cancer (NSCLC) patients treated with bemcentinib will be presented at the Society for Immunotherapy for Cancer (SITC) meeting being held on November 1-5, 2023 in San Diego, California.
October 31, 2023
·
3 min read
BerGenBio Announces Data from Biomarker Analyses in 2L NSCLC
BerGenBio ASA announced that a poster presentation detailing additional data from a Phase II trial of bemcentinib in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® in second line Non-Small Cell Lung Cancer patients was presented on November 4th at the 2023 Society of Immunotherapy of Cancer Annual Meeting.
November 6, 2023
·
3 min read
Additional data on BerGenBio’s selective AXL inhibitor bemcentinib to be presented at the 2023 ESMO meeting
BerGenBio ASA announced that a poster and an oral presentation summarizing completed studies with its lead product candidate bemcentinib will be presented at the upcoming European Society of Clinical Oncologists Annual Meeting 2023, to be held October 20-24 in Madrid.
October 16, 2023
·
3 min read
New Data on BerGenBio’s Selective AXL Inhibitor Bemcentinib Released Today at 2023 ESMO Meeting
BerGenBio ASA announced that the full results of its Phase 2 BGBC008 study of bemcentinib and pembrolizumab in second line Non-Small Cell Lung Cancer were presented during the European Society of Clinical Oncologists Annual Meeting 2023.
October 23, 2023
·
3 min read
BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer
BerGenBio ASA announced that additional clinical data of bemcentinib in combination with chemotherapy and with immunotherapy in Non-Small Cell Lung Cancer have been recently published and accepted for presentation at two upcoming international oncology conferences.
August 22, 2023
·
2 min read
1 of 50,927
Next